A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study).
about
Belatacept for kidney transplant recipientsBelatacept for kidney transplant recipientsBelatacept for the prophylaxis of organ rejection in kidney transplant patients: an evidence-based review of its place in therapyProspective Clinical Testing of Regulatory Dendritic Cells in Organ TransplantationThe Influence of Immunosuppressive Agents on the Risk of De Novo Donor-Specific HLA Antibody Production in Solid Organ Transplant RecipientsNovel Immune Check-Point Regulators in Tolerance MaintenanceDysglycemia after renal transplantation: Definition, pathogenesis, outcomes and implications for managementCo-Stimulatory Blockade of the CD28/CD80-86/CTLA-4 Balance in Transplantation: Impact on Memory T Cells?Current state of renal transplant immunosuppression: Present and futureTempering allorecognition to induce transplant tolerance with chemically modified apoptotic donor cellsFuture prospects in immunosuppression for liver transplantationCorticosteroid and calcineurin inhibitor sparing regimens in kidney transplantationSignificance of T helper 17 immunity in transplantationInduction therapy in heart transplantation: where are we now?Biologics in renal transplantationEpstein-Barr virus infection and posttransplant lymphoproliferative disorderDoes belatacept improve outcomes for kidney transplant recipients? A systematic reviewLong-term outcomes of children after solid organ transplantationInfection in Organ Transplantation.The future direction and unmet needs of transplant immunosuppression.Methylation of FOXP3 TSDR Underlies the Impaired Suppressive Function of Tregs from Long-term Belatacept-Treated Kidney Transplant PatientsA novel monoclonal antibody to CD40 prolongs islet allograft survivalCentral memory CD8+ T lymphocytes mediate lung allograft acceptance.Rapamycin ameliorates the CTLA4-Ig-mediated defect in CD8(+) T cell immunity during gammaherpesvirus infection.Graft Function and Intermediate-Term Outcomes of Kidney Transplants Improved in the Last Decade: Analysis of the United States Kidney Transplant Database.T-cell co-stimulatory blockade in kidney transplantation: back to the benchBelatacept-based immunosuppression in de novo liver transplant recipients: 1-year experience from a phase II randomized study.Selective targeting of human alloresponsive CD8+ effector memory T cells based on CD2 expression.Costimulatory pathways in transplantation.Risk evaluation and mitigation strategy programs in solid organ transplantation: the promises of information technologyBelatacept and sirolimus prolong nonhuman primate renal allograft survival without a requirement for memory T cell depletion.LFA-1-specific therapy prolongs allograft survival in rhesus macaques.The allo- and viral-specific immunosuppressive effect of belatacept, but not tacrolimus, attenuates with progressive T cell maturationRenal transplantation using belatacept without maintenance steroids or calcineurin inhibitors.GVHD after haploidentical transplantation: a novel, MHC-defined rhesus macaque model identifies CD28- CD8+ T cells as a reservoir of breakthrough T-cell proliferation during costimulation blockade and sirolimus-based immunosuppressionImmunosuppressive Medications.Use of CTLA4Ig for induction of mixed chimerism and renal allograft tolerance in nonhuman primatesNuclear calcium is required for human T cell activation.Prolonged, low-dose anti-thymocyte globulin, combined with CTLA4-Ig, promotes engraftment in a stringent transplant model.Five-year safety and efficacy of belatacept in renal transplantation
P2860
Q24187867-8E5F7D81-C016-49C5-88BF-B0B375500300Q24200801-90611FBC-D176-41FE-9F49-FDF8ADC90C91Q26745773-1801707F-1838-41FE-9B7C-34657B0F6B8EQ26767458-67B7C368-7C7D-43EF-AA9E-41C4F28C0F4FQ26774993-2A06380A-F729-4314-A0C1-8A0B7677F080Q26782789-A7B8FBE3-8EA5-4697-893F-0E4825486D7EQ26795773-14EFA10E-11E7-4F34-99EC-23C28AA2B747Q26796099-D1CCE55F-9F58-4E6D-8551-9C0265656990Q26829789-2640D975-28F0-4247-8BDF-AD6F9ECF7913Q26851647-5327D5D0-21E0-42D7-B889-D246F552D008Q26860486-419355FA-E853-4693-A11D-CF94636419F9Q26992343-0044153A-B8F3-4BF8-B17C-3EB77129E624Q26998887-3D255615-C7A6-435C-BA1F-1CC8E1F614A9Q26999269-F1077747-83FD-47A9-A99D-292CBA4A685EQ27009997-11C4BB25-6D43-4F55-ADE9-9DF42C72B6C8Q27024229-516D97AB-ED91-4C1C-B075-AC0C04365557Q28084644-FCB6F8F3-E9E6-4059-9501-ADB64AAB46CFQ28660815-5FC6A1AD-C91C-4EA0-8A9C-79F0315FA65DQ30238810-B1405874-2BDE-47F6-AAEA-F2F772EEA0C4Q30277037-2D4FD7F7-497C-483B-8E6D-3C67DD0DBF8CQ30360800-CDB09BA5-AF49-487B-AB41-D1963DC57570Q30417821-824E6A46-D00F-4BA1-86D8-D3B192D07D5DQ30573064-E7833330-8857-4FEE-8838-8E030D559E8BQ33559006-920A82EA-45A2-417B-A79D-43637BBB1BA3Q33779071-C6056720-EB93-4BEB-967F-20995A09B73BQ33873078-D4A6E8D4-7EB6-41F6-AB14-F16A2DD20F52Q34074790-152E5291-334A-4F84-AF66-C92A395F9B18Q34149246-84E3F1C9-B200-402E-A8D1-1A3CA5112C49Q34187594-143086D0-88A6-4B3E-BDD9-6AD719F1FC5FQ34235791-B7AA0341-22DF-498B-8BC7-06F07E3C8946Q34322116-D0FE6E36-63E3-4B6E-BFE9-DFD381AB9E4EQ34364120-47B3CC5B-EDA8-4EE4-8EBE-348E0108241AQ34400561-C55EDFB0-1CC1-4E04-85F2-F8AB8373895EQ34412887-AFE9F410-2220-438F-8BEE-9FAB5C83BAA5Q34450497-E33B818C-0932-46E3-8615-021CFFC203D8Q34484801-DB231758-348A-4ED0-A938-9580F9376C7EQ34536503-2D20DD35-7BB8-4B92-9F3B-B13C5E941DB2Q34544029-FDEC1D22-5A88-43CB-9BE7-2B3AF2C17D0AQ34551797-9FB56691-DF32-49EA-BAC3-D673D5E95459Q34621558-A9C59826-4A47-4813-A563-A4DF35A3AF92
P2860
A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study).
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
A phase III study of belatacep ...... nt recipients (BENEFIT study).
@en
A phase III study of belatacep ...... in renal transplant recipients
@nl
type
label
A phase III study of belatacep ...... nt recipients (BENEFIT study).
@en
A phase III study of belatacep ...... in renal transplant recipients
@nl
prefLabel
A phase III study of belatacep ...... nt recipients (BENEFIT study).
@en
A phase III study of belatacep ...... in renal transplant recipients
@nl
P2093
P1476
A phase III study of belatacep ...... nt recipients (BENEFIT study).
@en
P2093
B Bresnahan
B Charpentier
C P Larsen
F Vincenti
G A Mondragon-Ramirez
G Di Russo
L Rostaing
P2860
P304
P356
10.1111/J.1600-6143.2009.03005.X
P407
P577
2010-03-01T00:00:00Z